Baré Marisa, Alcantara Manuel Jesús, Gil Maria José, Collera Pablo, Pont Marina, Escobar Antonio, Sarasqueta Cristina, Redondo Maximino, Briones Eduardo, Dujovne Paula, Quintana Jose Maria
Clinical Epidemiology and Cancer Screening, Parc Taulí Sabadell-University Hospital, Parc Taulí 1, 08208, Sabadell, Spain.
Obstetrics, Gynecology and Preventive Medicine Department, Autonomous University of Barcelona-UAB, Cerdanyola del Vallès, Spain.
BMC Health Serv Res. 2018 Jan 29;18(1):49. doi: 10.1186/s12913-018-2839-x.
To validate and recalibrate the CR- POSSUM model and compared its discriminatory capacity with other European models such as POSSUM, P-POSSUM, AFC or IRCS to predict operative mortality in surgery for colorectal cancer.
Prospective multicenter cohort study from 22 hospitals in Spain. We included patients undergoing planned or urgent surgery for primary invasive colorectal cancers between June 2010 and December 2012 (N = 2749). Clinical data were gathered through medical chart review. We validated and recalibrated the predictive models using logistic regression techniques. To calculate the discriminatory power of each model, we estimated the areas under the curve - AUC (95% CI). We also assessed the calibration of the models by applying the Hosmer-Lemeshow test.
In-hospital mortality was 1.5% and 30-day mortality, 1.7%. In the validation process, the discriminatory power of the CR-POSSUM for predicting in-hospital mortality was 73.6%. However, in the recalibration process, the AUCs improved slightly: the CR-POSSUM reached 75.5% (95% CI: 67.3-83.7). The discriminatory power of the CR-POSSUM for predicting 30-day mortality was 74.2% (95% CI: 67.1-81.2) after recalibration; among the other models the POSSUM had the greatest discriminatory power, with an AUC of 77.0% (95% CI: 68.9-85.2). The Hosmer-Lemeshow test showed good fit for all the recalibrated models.
The CR-POSSUM and the other models showed moderate capacity to discriminate the risk of operative mortality in our context, where the actual operative mortality is low. Nevertheless the IRCS might better predict in-hospital mortality, with fewer variables, while the CR-POSSUM could be slightly better for predicting 30-day mortality.
Registered at: ClinicalTrials.gov Identifier: NCT02488161.
验证并重新校准CR-POSSUM模型,并将其与其他欧洲模型(如POSSUM、P-POSSUM、AFC或IRCS)在预测结直肠癌手术患者手术死亡率方面的区分能力进行比较。
来自西班牙22家医院的前瞻性多中心队列研究。我们纳入了2010年6月至2012年12月期间接受原发性浸润性结直肠癌计划手术或急诊手术的患者(N = 2749)。通过病历审查收集临床数据。我们使用逻辑回归技术验证并重新校准了预测模型。为计算每个模型的区分能力,我们估计了曲线下面积-AUC(95%CI)。我们还通过应用Hosmer-Lemeshow检验评估了模型的校准情况。
住院死亡率为1.5%,30天死亡率为1.7%。在验证过程中,CR-POSSUM预测住院死亡率的区分能力为73.6%。然而,在重新校准过程中,AUC略有提高:CR-POSSUM达到75.5%(95%CI:67.3-83.7)。重新校准后,CR-POSSUM预测30天死亡率的区分能力为74.2%(95%CI:67.1-81.2);在其他模型中,POSSUM的区分能力最强,AUC为77.0%(95%CI:68.9-85.2)。Hosmer-Lemeshow检验显示所有重新校准后的模型拟合良好。
在我们实际手术死亡率较低的情况下,CR-POSSUM和其他模型在区分手术死亡风险方面表现出中等能力。然而,IRCS可能在预测住院死亡率方面表现更好,变量更少,而CR-POSSUM在预测30天死亡率方面可能略胜一筹。
注册于:ClinicalTrials.gov标识符:NCT02488161。